Innovative medical solutions
for long-standing challenges
Our unique technology addresses the issues that arise from water-based delivery systems with a novel, proprietary, non-aqueous formulation. This innovative approach has been implemented in Gvoke® Pre-Filled Syringe (glucagon injection) and Gvoke HypoPen®.
Learn more about our Gvoke® offeringsSolutions for many therapeutic areas
We're currently developing innovative, ready-to-use solutions for various therapeutic categories to remove many associated treatment burdens and ultimately improve patients' lives.
See how we can helpProgress for severe hypoglycemia and epilepsy are just the start
While clinical trials are currently underway to investigate how Xeris' formulation technology can be applied for hypoglycemia and epilepsy management, Xeris' novel formulation also has the potential for use in single-use auto-injectors, prefilled syringes, ready-to-use vials, and pumps.
Uncover what tomorrow bringsA different approach
At Xeris, we're always looking for ways to really impact patients' lives. That's why we offer a novel formulation technology to bring ready-to-use, liquid-stable injectables to patients whose lives are often burdened by the “time of use” preparation routine.
Explore what we have to offer
You have chosen a link to an external site.
By clicking "ok", a new window will open.
Do you wish to continue?
OK No Thanks!Not opening? Check to see you have pop-ups enabled or copy link below in a new window.
We are proud to announce that as of October 5, 2021,
Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc
are subsidiaries of Xeris Biopharma Holdings, Inc.
Learn more about this announcement
No Thanks!
Not opening? Check to see you have pop-ups enabled or copy link below in a new window.
https://ir.xerispharma.com/